Related references
Note: Only part of the references are listed.Kit for the preparation of 111In-labeled pertuzumab injection for imaging response of HER2-positive breast cancer to trastuzumab (Herceptin)
Karen Lam et al.
APPLIED RADIATION AND ISOTOPES (2015)
Preclinical pharmacokinetics, biodistribution, radiation dosimetry and acute toxicity studies required for regulatory approval of a Clinical Trial Application for a Phase I/II clinical trial of 111In-BzDTPA-pertuzumab
Karen Lam et al.
NUCLEAR MEDICINE AND BIOLOGY (2015)
MicroPET/CT imaging of patient-derived pancreatic cancer xenografts implanted subcutaneously or orthotopically in NOD-scid mice using 64Cu-NOTA-panitumumab F(ab')2 fragments
Amanda J. Boyle et al.
NUCLEAR MEDICINE AND BIOLOGY (2015)
111In-Cetuximab-F(ab′)2 SPECT and 18F-FDG PET for Prediction and Response Monitoring of Combined-Modality Treatment of Human Head and Neck Carcinomas in a Mouse Model
Laura K. van Dijk et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Functional Imaging of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Using Cu-64-DOTA-Trastuzumab PET
Joanne E. Mortimer et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
Glypican-3-Targeted 89Zr PET Imaging of Hepatocellular Carcinoma
Jonathan G. Sham et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Imaging of Epidermal Growth Factor Receptor Expression in Head and Neck Cancer with SPECT/CT and 111In-Labeled Cetuximab-F(ab′)2
Laura K. van Dijk et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
64Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer
Kenji Tamura et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
Sandra M. Swain et al.
LANCET ONCOLOGY (2013)
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Luca Gianni et al.
LANCET ONCOLOGY (2012)
Lapatinib and 17AAG Reduce 89Zr-Trastuzumab-F(ab')2 Uptake in SKBR3 Tumor Xenografts
Thijs H. Oude Munnink et al.
MOLECULAR PHARMACEUTICS (2012)
Trastuzumab: updatedmechanisms of action and resistance in breast cancer
Thuy Vu et al.
FRONTIERS IN ONCOLOGY (2012)
A comparison of In-111- or Cu-64-DOTA-trastuzumab Fab fragments for imaging subcutaneous HER2-positive tumor xenografts in athymic mice using microSPECT/CT or microPET/CT
Conrad Chan et al.
EJNMMI RESEARCH (2011)
In vitro and in vivo pre-clinical analysis of a F(ab')(2) fragment of panitumumab for molecular imaging and therapy of HER1-positive cancers
Karen J. Wong et al.
EJNMMI RESEARCH (2011)
Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer
E. C. Dijkers et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Antitumor Effects and Normal-Tissue Toxicity of 111In-Nuclear Localization Sequence-Trastuzumab in Athymic Mice Bearing HER-Positive Human Breast Cancer Xenografts
Danny L. Costantini et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics
Jason A. Wilken et al.
JOURNAL OF OVARIAN RESEARCH (2010)
Associations between the uptake of In-111-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts
Kristin McLarty et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2009)
Micro-SPECT/CT with 111In-DTPA-Pertuzumab Sensitively Detects Trastuzumab-Mediated HER2 Downregulation and Tumor Response in Athymic Mice Bearing MDA-MB-361 Human Breast Cancer Xenografts
Kristin McLarty et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
Jeffrey S. Ross et al.
ONCOLOGIST (2009)
HER2 status and benefit from adjuvant trastuzumab in breast cancer
Soonmyung Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
PET versus SPECT: strengths, limitations and challenges
Arman Rahmim et al.
NUCLEAR MEDICINE COMMUNICATIONS (2008)
Partial-volume effect in PET tumor imaging
Marine Soret et al.
JOURNAL OF NUCLEAR MEDICINE (2007)
Molecular imaging as a tool for personalized and targeted anticancer therapy
K. McLarty et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab
CW Adams et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2
KE Longva et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using In-111-trastuzumab (Herceptin) Fab fragments
Y Tang et al.
NUCLEAR MEDICINE AND BIOLOGY (2005)
Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors
PM Smith-Jones et al.
NATURE BIOTECHNOLOGY (2004)
Rapid blood clearance of injected mouse IgG2a in SCID mice
RB Michel et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2002)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
H Maeda et al.
JOURNAL OF CONTROLLED RELEASE (2000)
Share Paper
